(redirected from leuprolide acetate)
Also found in: Medical.

leuprorelin, leuprolide

n leuprorelina, leuprolida
English-Spanish/Spanish-English Medical Dictionary Copyright © 2006 by The McGraw-Hill Companies, Inc. All rights reserved.
References in periodicals archive ?
- Lupron (leuprolide acetate), a gonadotropin-releasing hormone agonist, is the only approved drug for uterine fibroids.
Eligard: leuprolide acetate in a novel sustained-release delivery system.
Analysis of subsequent surgery rates among endometriosis patients who underwent surgery with and without concomitant leuprolide acetate therapy.
The patient was treated with leuprolide acetate (380 [micro]g/kg IM single dose; Lupron, TAP Pharmaceuticals Inc, Lake Forest, IL, USA) and meloxicam (1 mg/kg IM once).
PEARL 1 (10) and PEARL 2 (11) demonstrated Esmya's efficacy when compared to a placebo, and highlighted its fewer side effects in comparison to leuprolide acetate, a synthetic gonadotropin-releasing hormone that has been used preoperatively in uterine fibroids patients.
I am not aware of any head-to-head studies comparing hot flashes between GnRH agonists (in particular, leuprolide acetate) and elagolix.
Vazquez et al., "Ulipristal acetate versus leuprolide acetate for uterine fibroids," New England Journal of Medicine, vol.
She was treated with an injection of 11.25 mg leuprolide acetate, a long-acting LHRH agonist, without abandoning tamoxifen therapy.
A post-hoc analysis was also recently conducted of the ICELAND study --a large, multicentre, European study demonstrating similar efficacy and tolerability between continuous and intermittent ADT with leuprolide acetate (Eligard) in non-metastatic prostate cancer.
Among various GnRH agonists, buserelin 0.5 mg (14), triptorelin 0.2 mg (15,16) and leuprolide acetate (0.5-4 mg) (17,18) have been utilized and almost all studies compared the outcomes of GnRH agonist triggered cycles with the cycles triggered with hCG.
Leuprolide acetate salt (Sigma-Aldrich, Italy) was dissolved in 0.9% NaCl solution and also administered subcutaneously to CASQ1-null female mice at a final dose of 100 ng/g of body weight every day for 1 month.